

Special Issue

Precision Medicine and Targeted Therapies in Neuroblastoma

Message from the Guest Editor

Neuroblastoma, a childhood embryonal tumor arising from sympathoadrenal precursors, remains a significant clinical challenge. Patients with high-risk disease are treated with toxic combinations of chemotherapy, radiation therapy, and anti-GD2 immunotherapy, and yet 5-year progression free survival for these patients remains less than 65%, and survivors are left with significant morbidities. Preclinical studies have identified the role of additional oncogenic pathways in disease resistance, including immortalization through telomere maintenance mechanisms, alternative metabolomics, and the activation of orthogonal oncogenic pathways, among others. Novel approaches are needed to attack these critical nodes of neuroblastoma viability, both through the development of new therapeutics and through the repurposing of available agents. Innovative study designs will be necessary, making use of integrative diagnostics and theranostics to personalize therapy, and using combination therapies for synergistic efficacy and reduced toxicity. We invite submissions on basic laboratory, preclinical, and clinical research highlighting these paths to improved outcomes for children with neuroblastoma.

Guest Editor

Dr. Nilay Shah

Division of Hematology/Oncology/Blood and Marrow Transplantation,
Nationwide Children's Hospital, Columbus, OH 43205, USA

Deadline for manuscript submissions

30 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/229122

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)